

## Technology Guidance

# Ustekinumab biosimilar for treating inflammatory conditions

Technology Guidance from the MOH Drug Advisory Committee

### Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial for listing on the MOH Standard Drug List (SDL). The decision was based on the acceptable pricing proposal from the company.

### Funding status

SDL subsidy will apply from 1 April 2026 to all registered indications of ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial in Singapore.

SDL subsidy **does not** apply to other brand(s), formulation(s) or strength(s) of ustekinumab.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

#### About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

*Find out more about ACE at [www.ace-hta.gov.sg/about](http://www.ace-hta.gov.sg/about)*

#### © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore  
Email: [ACE\\_HTA@moh.gov.sg](mailto:ACE_HTA@moh.gov.sg)

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.